- Trials with a EudraCT protocol (169)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
169 result(s) found for: Gene Drive.
Displaying page 1 of 9.
EudraCT Number: 2018-000156-18 | Sponsor Protocol Number: 301OTC02 | Start Date*: 2018-08-15 | |||||||||||
Sponsor Name:Ultragenyx Pharmaceutical, Inc. | |||||||||||||
Full Title: A Long-Term Follow-up Study to Evaluate the Safety and Efficacy of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Adults with Lat... | |||||||||||||
Medical condition: Ornithine transcarbamylase deficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001878-28 | Sponsor Protocol Number: 307-201 | Start Date*: 2019-12-17 | |||||||||||
Sponsor Name:BioMarin Pharmaceutical Inc. | |||||||||||||
Full Title: A Phase 1/2 Open-Label, Dose Escalation Study to Determine the Safety and Efficacy of BMN 307, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Phenylalanine Hydroxylase in Subjects... | |||||||||||||
Medical condition: Phenylketonuria | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003430-25 | Sponsor Protocol Number: 101HEMB02 | Start Date*: 2017-05-18 | |||||||||||
Sponsor Name:Ultragenyx Pharmaceutical, Inc. | |||||||||||||
Full Title: A Long-Term Follow-up Study to Evaluate the Safety, Tolerability, and Efficacy of Adeno-Associated Virus (AAV) rh10-Mediated Gene Transfer of Human Factor IX in Adults With Moderate/Severe to Sever... | |||||||||||||
Medical condition: Moderate/severe to severe hemophilia B | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002502-31 | Sponsor Protocol Number: RP-L102-0118 | Start Date*: 2018-10-31 | |||||||||||
Sponsor Name:Rocket Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the FANCA Gene (Orphan Drug) in Patients with Fanconi Anemi... | |||||||||||||
Medical condition: Fanconi anemia (subtype A) | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003491-41 | Sponsor Protocol Number: AG-CLI-0206-LTFU | Start Date*: 2016-12-12 | |||||||||||
Sponsor Name:AnGes Inc. | |||||||||||||
Full Title: A Long Term Follow-up Study of AMG0001 in Subjects with Critical Limb Ischemia | |||||||||||||
Medical condition: Critical limb ischemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BE (Ongoing) FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012595-27 | Sponsor Protocol Number: A8081007 | Start Date*: 2010-01-20 | |||||||||||
Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF PF 02341066 VERSUS STANDARD OF CARE CHEMOTHERAPY (PEMETREXED OR DOCETAXEL) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (... | |||||||||||||
Medical condition: ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) NL (Completed) DE (Completed) PL (Completed) ES (Completed) HU (Completed) FR (Completed) GR (Completed) IT (Completed) IE (Completed) BG (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003098-26 | Sponsor Protocol Number: 3144A1-201-WW | Start Date*: 2006-06-06 |
Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc. | ||
Full Title: Phase 2 Study of HKI-272 in Subjects with Advanced Breast Cancer | ||
Medical condition: Breast cancer is the most frequently diagnosed malignancy and the second most common cause of cancer related deaths in women. HER2 is a member of the epidermal growth factor receptor (EGFR) family ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: BE (Completed) FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-022978-14 | Sponsor Protocol Number: A8081013 | Start Date*: 2011-02-10 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: PHASE 1B OPEN-LABEL STUDY OF THE SAFETY AND CLINICAL ACTIVITY OF CRIZOTINIB (PF-02341066) IN TUMORS WITH GENETIC EVENTS INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK ) GENE LOCUS | |||||||||||||
Medical condition: Treatment of tumors with translocation, mutation, or amplification of the anaplastic lymphoma kinase (ALK)gene locus. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012504-13 | Sponsor Protocol Number: A8081005 | Start Date*: 2010-01-20 | |||||||||||
Sponsor Name:Pfizer Inc 235 East 42nd Street, New York, NY10017 | |||||||||||||
Full Title: PHASE 2, OPEN-LABEL SINGLE ARM STUDY OF THE EFFICACY AND SAFETY OF PF 02341066 IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING A TRANSLOCATION OR INVERSION INVOLVING THE ANAP... | |||||||||||||
Medical condition: metastatic non-small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) NL (Completed) DE (Completed) ES (Completed) HU (Completed) PL (Completed) GR (Completed) IT (Completed) FR (Completed) IE (Completed) BG (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003023-30 | Sponsor Protocol Number: 401GSDIA01 | Start Date*: 2018-11-27 | |||||||||||
Sponsor Name:Ultragenyx Pharmaceutical, Inc. | |||||||||||||
Full Title: A Phase 1/2, Open-Label Safety and Dose-Finding Study of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Glucose-6-Phosphatase (G6Pase) in Adults with Glycogen Storage Dise... | |||||||||||||
Medical condition: Glycogen Storage Disease Type Ia (GSDIa). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001596-14 | Sponsor Protocol Number: TYR300-101 | Start Date*: 2023-06-26 | |||||||||||||||||||||||||||||||
Sponsor Name:Tyra Biosciences, Inc. | |||||||||||||||||||||||||||||||||
Full Title: A Multicenter, Open-label Phase 1/2 Study of TYRA 300 in Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations (SURF 301) | |||||||||||||||||||||||||||||||||
Medical condition: Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003603-18 | Sponsor Protocol Number: 331-201 | Start Date*: 2022-10-06 | ||||||||||||||||
Sponsor Name:BioMarin Pharmaceutical Inc. | ||||||||||||||||||
Full Title: A Phase 1/2, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Efficacy of BMN 331, an Adeno-Associated Virus (AAV) Vector-Mediated Gene Transfer of Human SERPING1, in Su... | ||||||||||||||||||
Medical condition: Hereditary Angioedema (HAE) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001057-40 | Sponsor Protocol Number: 301OTC01 | Start Date*: 2017-03-14 | |||||||||||
Sponsor Name:Ultragenyx Pharmaceutical, Inc. | |||||||||||||
Full Title: A Phase 1/2, Open-Label Safety and Dose-Finding Study of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Adults with Late-Onset OT... | |||||||||||||
Medical condition: Ornithine transcarbamylase deficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004486-86 | Sponsor Protocol Number: SRA737-01 | Start Date*: 2016-04-25 | |||||||||||
Sponsor Name:Sierra Oncology, Inc. | |||||||||||||
Full Title: A Phase 1/2 Trial of SRA737 (a Chk1 Inhibitor) Administered Orally in Subjects with Advanced Cancer | |||||||||||||
Medical condition: Patients with histologically or cytologically proven advanced solid tumours, refractory to conventional treatment, or for which no conventional therapy is considered appropriate by the Investigator. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001955-29 | Sponsor Protocol Number: 024PKAN15004 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Retrophin, Inc. | |||||||||||||
Full Title: Efficacy, Safety, and Tolerability of Fosmetpantotenate (RE-024), a Phosphopantothenate replacement therapy, in patients with Pantothenate Kinase-associated Neurodegeneration (PKAN): A Randomized, ... | |||||||||||||
Medical condition: Pantothenate kinase associated neurodegeneration (PKAN), an autosomal recessive genetic disorder, the most common form of Neurodegeneration with Brain Iron Accumulation (NBIA). It is a progressive,... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Prematurely Ended) GB (Prematurely Ended) CZ (Prematurely Ended) NO (Completed) FR (Completed) PL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004370-34 | Sponsor Protocol Number: POM-003 | Start Date*: 2018-04-09 | |||||||||||
Sponsor Name:Amicus Therapeutics, Inc. | |||||||||||||
Full Title: A Prospective Study in Subjects with Late-onset Pompe Disease who are Currently Being Treated with Enzyme Replacement Therapy | |||||||||||||
Medical condition: Late-onset Pompe disease (LOPD) in subjects receiving standard-of-care enzyme replacement therapy (ERT) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004473-27 | Sponsor Protocol Number: 401GSDIA02 | Start Date*: 2021-08-25 | |||||||||||
Sponsor Name:Ultragenyx Pharmaceutical Inc. | |||||||||||||
Full Title: A Long-Term Follow-up Study to Evaluate the Safety and Efficacy of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Glucose-6-Phosphatase (G6Pase) in Adults with Glycogen St... | |||||||||||||
Medical condition: Glycogen Storage Disease Type Ia (GSDIa). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021336-33 | Sponsor Protocol Number: A8081014 | Start Date*: 2010-12-30 | |||||||||||
Sponsor Name:Pfizer Inc 235 East 42nd Street, New York, NY10017 US | |||||||||||||
Full Title: PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED PATIENTS WITH NON-SQUAMOUS CARCINOMA OF ... | |||||||||||||
Medical condition: non-small cell lung cancer (NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) FI (Completed) IE (Completed) AT (Completed) IT (Completed) GB (Completed) BE (Completed) NL (Completed) DK (Prematurely Ended) PT (Completed) NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003573-34 | Sponsor Protocol Number: 270-302 | Start Date*: 2018-02-23 |
Sponsor Name:BioMarin Pharmaceutical Inc. | ||
Full Title: A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector–Mediated Gene Transfer of Human Factor VIII at a dose of 4E13 vg/kg in Hemoph... | ||
Medical condition: Haemophilia A | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) FR (Completed) BE (Completed) IT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2007-003359-35 | Sponsor Protocol Number: GAU-CL-202 | Start Date*: 2007-12-19 |
Sponsor Name:Amicus Therapeutics, Inc. | ||
Full Title: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF AT2101 IN TREATMENT-NAIVE ADULT PATIENTS WITH TYPE 1 GAUCHER DISEASE | ||
Medical condition: Type 1 Gaucher Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) DE (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.